Skip to main content

Table 2 Proportion of patients who received guideline-indicated treatment for which they were eligible according to comorbidity

From: Association of treatments for acute myocardial infarction and survival for seven common comorbidity states: a nationwide cohort study

Guideline-indicated care Treatments received % (N)
Diabetes mellitus COPD or asthma Hypertension Chronic heart failure Chronic renal failure Cerebrovascular disease Peripheral vascular disease Number of comorbidities
Pharmacological therapies 0 1 2 ≤
 Acute aspirin 89.8 (66,818) 90.7 (54,297) 91.3 (182,918) 87.2 (14,865) 87.9 (14,936) 88.5 (24,549) 88.2 (13,341) 86.4 (201,860) 91.0 (155,972) 90.1 (91,927)
 Aspirin at discharge 86.2 (88,601) 86.1 (64,560) 86.8 (225,028) 81.5 (21,971) 84.2 (20,580) 84.0 (35,427) 84.5 (19,439) 85.0 (207,794) 86.4 (178,134) 85.8 (124,459)
 P2Y12 inhibitors at discharge 40.5 (41,639) 38.6 (29,058) 39.8 (102,566) 31.9 (8669) 42.7 (10,609) 36.6 (15,726) 35.6 (8199) 38.1 (81,619) 38.3 (77,834) 39.4 (57,546)
 β-blockers at discharge 72.0 (32,712) 56.7 (13,980) 74.9 (90,334) 71.4 (16,417) 67.6 (6994) 66.3 (12,766) 67.2 (7173) 75.2 (107,956) 74.2 (73,120) 69.2 (44,117)
 ACE inhibitors/ARBs at discharge 82.6 (81,177) 78.2 (37,411) 80.6 (136,249) 77.5 (19,599) 72.0 (10,092) 74.9 (20,538) 76.9 (12,333) 74.7 (119,461) 77.8 (97,090) 80.7 (90,851)
 Statins at discharge 84.8 (89,259) 83.5 (64,424) 85.0 (224,238) 77.0 (21,627) 80.7 (20,249) 81.5 (35,656) 83.0 (19,728) 82.6 (203,064) 84.1 (175,625) 83.8 (124,997)
Aldosterone antagonists
 At discharge 30.1 (520) 33.4 (117) 32.6 (519) 38.1 (408) N/A 33.0 (114) 30.0 (68) 0.0 (0) 30.5 (151) 32.6
6 (623)
 At admission or discharge 34.5 (597) 37.7 (132) 36.9 (587) 42.3 (453) N/A 36.4 (126) 35.2 (80) 0.0 (0) 33.3 (165) 36.8
8 (708)
Non-invasive therapies
 Echocardiogram 56.7 (65,980) 56.6 (48,031) 57.5 (165,339) 54.2 (17,154) 56.7 (16,429) 53.5 (26,006) 57.7 (15,145) 52.0 (140,591) 55.7 (126,655) 57.1 (94,299)
 ECG 95.5 (116,764) 95.7 (85,337) 96.0 (290,259) 93.8 (31,722) 96.1 (29,804) 95.6 (49,612) 95.1 (26,268) 93.9 (263,563) 95.6 (227,863) 95.7 (167,033)
 Cardiac rehabilitation 73.2 (82,843) 73.8 (60,629) 75.6 (212,835) 62.8 (18,560) 66.0 (17,914) 67.5 (31,024) 72.2 (18,296) 74.8 (200,239) 76.0 (169,622) 72.0 (114,624)
 Smoking cessation advice 16.7 (9464) 19.4 (9819) 17.4 (24,966) 8.3 (1248) 11.8 (1461) 14.0 (3326) 16.6 (2693) 20.2 (32,897) 18.4 (22,015) 15.9 (13,102)
 Dietary advice 34.8 (40,140) 32.7 (27,584) 33.7 (96,587) 26.2 (8066) 35.0 (9796) 30.7 (14,630) 30.9(8052) 28.2 (76,044) 32.1 (72,932) 33.6 (54,844)
Invasive therapies
 Early invasive coronary procedures 51.2 (59,241) 48.6 (41,003) 54.4 (157,090) 28.7 (8864) 36.2 (10,158) 37.9 (18,190) 46.4 (12,145) 57.7 (157,354) 55.5 (126,868) 46.9 (76,944)
Cumulative treatment score—median (IQR) 66.7 (50.0–87.5) 66.7 (50.0–85.7) 66.7 (54.5–87.5) 60.0 (42.9–80.0) 63.6 (45.5–83.3) 62.5 (45.5–81.8) 63.6 (50.0–83.3) 66.7 (50.0–81.8) 66.7 (50.0–85.7) 66.7 (50.0–85.7)
Percentage of optimal care receipt 14.3 (14,449) 14.0 (12,512) 15.1 (45,657) 8.6 (2916) 13.2 (4101) 12.3 (6377) 13.2 (3655) 13.0 (36,413) 14.5 (34,599) 14.0 (24,355)
  1. COPD chronic obstructive pulmonary disease, ACE inhibitors angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, ECG electrocardiogram, N/A not applicable as do not meet eligibility criteria; full eligibility criteria in appendices; smoking cessation advice given to those with smoking history; acute aspirin includes only those with direct admission who were not already on aspirin or contraindicated; early invasive coronary procedures include primary PCI or thrombolysis within 12 h for STEMI and coronary angiography or PCI within 72 h for NSTEMI patients; patients were classified as ineligible if a treatment was listed as contraindicated, not indicated, or not applicable; if the patient declined treatment as recorded in MINAP; or if the patient was hospitalised prior to the publication year of treatment recommendation in the guidelines